Press Release on the financial results of the Company for the quarter ended September 30, 2026

Ref: BHL/ STEX 47/ 2026-27 Date: October 17, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex Bandra (East) Mumbai – 400 001 Mumbai-400051 Scrip Code: 539872 Symbol: BAJAJHCARE Sub: Press Release for the quarter ended September 30, 2026 Dear Sir/Madam, Please find enclosed the Press Release on the financial results of the Company for the quarter ended September 30, 2026. Kindly take the same on record. Thanking you. Yours faithfully, For and on behalf of Bajaj Healthcare Limited Monica Tanwar Company Secretary & Compliance Officer Encl: As above BAJAJ HEALTHCARE LIMITED Registered Office: 602-606, Bhoomi Velocity Infotech Park, Road No 23, Wagle Industrial Estate, Thane – 400 604 Website: www.bajajhealth.com Email: investors@bajajhealth.com CIN: L99999MH1993PLC072892 INVESTOR RELEASE Bajaj Healthcare reports Q2 & H1 FY27 results Revenue Up 18.9% YoY; EBITDA Up 12.2% and PAT Up 26.9% YoY Mumbai, 17th October 2026: Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its unaudited financial results for the quarter and half year ended 30th September 2026. Highlights of Q2 FY27 Results ● Revenue from operations at Rs. 175.9 Crore, up 18.9% YoY and 6.2% sequentially ● Gross profit at Rs. 85.4 Crore, up 12.4% YoY; gross margin at 48.3%, in line with Q1 FY27 ● EBITDA at Rs. 32.1 Crore, up 12.2% YoY; EBITDA margin improved to 18.2% from 17.8% in Q1 FY27 ● Profit after tax at Rs. 14.1 Crore, up 26.9% YoY; PAT margin improved to 8.0% from 7.5% in Q2 FY26 Highlights of H1 FY27 Results ● Revenue from operations at Rs. 341.5 Crore, up 15.1% YoY ● Gross profit at Rs. 165.8 Crore, up 14.2% YoY; gross margin at 48.3% ● EBITDA at Rs. 61.7 Crore, up 14.2% YoY; EBITDA margin at 18.1% ● Profit after tax at Rs. 27.8 Crore, up 21.1% YoY; PAT margin improved to 8.1% from 7.7% in H1 FY26 Business Performance API — Domestic Domestic API sales for the quarter were Rs. 71.6 Crore, as compared to Rs. 76.3 Crore in Q2 FY26. For the first half of the year, domestic API sales grew 10.1% YoY to Rs. 163.9 Crore. API — Exports API export sales were Rs. 62.6 Crore for the quarter, up 28.5% YoY from Rs. 48.7 Crore in Q2 FY26 and 25.1% sequentially. Formulations Formulations revenue was Rs. 41.7 Crore for the quarter, up ~82% YoY from Rs. 22.9 Crore in Q2 FY26 and ~79% sequentially. During the quarter, the Company launched Cenobamate through its marketing partners in India. The segment has normalised as the Company had expected at the end of Q1 FY27. Quarterly Business Updates • Bajaj Healthcare became the first company in India to receive approval from the Drug Controller General of India (DCGI) to manufacture and market Cenobamate API and Tablets in six strengths, following the SEC recommendation received in Q1 FY27. Cenobamate is a next-generation anti-seizure medication for the treatment of partial-onset seizures in adults. • Commercial launch of Cenobamate Tablets commenced in Sept 2026 through 8 marketing partners. • India Ratings & Research upgraded the Company’s long-term rating from INA A-/Stable to IND A/Stable and affirmed the short-term rating at IND A1, reflecting the strengthened balance sheet and improved operating performance • On the regulatory front, o the Company is progressing with the ANVISA GMP certification process and has identified 17 products for CBPF submission, emphasizing its business growth in Brazil. o A total of 12 CEPs has been filed to date, of which eight have been approved and four remain under review. o Secured KDMF approvals for two additional products during the last quarter, bringing the total number of 17 KDMF registered with MFDS. o The Company has registered three products under the whitelist registration process in Egypt, with plans to add 10 more products in subsequent phases Management Commentary Commenting on the Results, Mr. Anil Jain – Managing Director said, “We have delivered a strong second quarter, with healthy growth across key financial parameters. In fact, our API exports and formulations business combined crossed Rs. 100 Cr in revenue in Q2FY27. Further, revenue from operations grew 18.9% YoY to Rs. 175.9 Crore, EBITDA increased 12.2% YoY, with EBITDA margin improving sequentially to 18.2%, and PAT grew 26.9% YoY. For the first half, revenue grew 15.1% and PAT grew 21.1% YoY. As we had expected, formulations rebounded strongly, growing 82% YoY, while API exports grew 28.5% YoY. Further, we have received NCLT approval for acquisition of GenRx which will enable us to further expand our formulation capabilities. The quarter also marked an important milestone in our innovation journey. We became the first company in India to receive DCGI approval for Cenobamate API and Tablets, reinforcing our commitment to building a differentiated specialty portfolio. Our peptide facility remains on track for commissioning in Q4FY27 and the upgrade in our credit rating reflects the stronger balance sheet that we have built. With a strong foundation and clear priorities, we remain committed to delivering sustainable growth and enhancing long- term value for all our shareholders.” Financial Snapshot- Q2 & H1 FY27 (Rs.in Crore) Particulars Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q H1 FY27 H1 FY26 Y-o-Y API — Domestic 71.6 76.3 (6.1%) 92.3 (22.4%) 163.9 148.9 10.1% API — Exports 62.6 48.7 28.5% 50.1 25.1% 112.7 100.9 11.6% Formulations 41.7 22.9 82.0% 23.3 78.8% 65.0 47.0 38.4% Revenue from Operations 175.9 147.9 18.9% 165.6 6.2% 341.5 296.8 15.1% Gross Profit 85.4 76.0 12.4% 80.3 6.3% 165.8 145.1 14.2% Gross Margin (%) 48.3% 50.8% 48.3% 48.3% 48.5% EBITDA 32.1 28.6 12.2% 29.6 8.6% 61.7 54.0 14.2% EBITDA Margin (%) 18.2% 19.3% 17.8% 18.1% 18.2% PAT* 14.1 11.1 26.9% 13.7 2.9% 27.8 22.9 21.1% PAT Margin 8.0% 7.5% 8.3% 8.1% 7.7% Earnings Call The Company will host an earnings call on Monday, 19th October, 2026, at 5 PM IST, where senior management will discuss the Company’s performance and answer questions from participants. This call will be accessible through an audio dial-in and a webcast. Audio Conference Universal Dial In: +91 22 6280 1550 / +91 22 7115 8378 International Toll Free: Hong Kong : 800964448, UK : 08081011573, Singapore : 8001012045, USA : 18667462133 Pre-registration Please click here for pre-registration Webcast Details will be provided through the Company’s website, www.bajajhealth.com To participate in the audio call, please dial the numbers provided five to ten minutes ahead of the scheduled start time. A transcript of the event will be made available on the Company’s website following the call. Disclaimer This press release contains forward-looking statements based on current expectations, assumptions, and estimates. Actual results may differ materially due to various risks and uncertainties. The Company undertakes no obligation to update or revise these statements, except as required under applicable laws and regulations. About Bajaj Healthcare Limited Bajaj Healthcare Limited is a leading manufacturer of APIs, Intermediates and Formulations. Established in 1993, it has built a strong reputation for delivering high quality pharmaceutical products, nutraceuticals across various therapies. The Company operates state-of-the-art manufacturing facilities that are designed to meet the requirements of both regulated and emerging markets. With a strong global presence, BHL serves customers across Europe, USA, Australia, Middle East, and South America. Contacts Company: Investor Relations Advisors: MUFG Intime India Private Limited Mr. Rohan Parekh- CFO Ms. Prachi Ambre — prachi.ambre@in.mpms.mufg.com Email: investors@bajajhealth.com Mr. Irfan Raeen — irfan.raeen@in.mpms.mufg.com